Q-omics provides the consensus-scored MYO16 profile across patient tissues and cancer cell-line models. MYO16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYO16 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MYO16 RNA expression shows 14,777 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where MYO16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO16 survival associations across molecular data types. MYO16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO16 RNA expression–survival associations across cancer types. High MYO16 expression shows unfavorable associations in KIRP, THYM and BLCA, but favorable associations in UVM, ACC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MYO16 RNA expression.
This table summarizes MYO16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MYO16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO16 shows lower tumor expression in KIRC, THCA, BRCA, LIHC and UCEC and higher tumor expression in KICH. The KIRC box plot shows higher MYO16 RNA expression in normal versus tumor tissue (log2 FC = −0.176, t-test p < 0.001).
This table shows molecular features associated with MYO16 in patient tissues and cancer cell lines. In patient samples, MYO16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
